Overview

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Drotrecogin alfa activated
Protein C